Ryzneuta (Efbemalenograstim alfa)

Ryzneuta (efbemalenograstim alfa) is a leukocyte growth factor used for reducing the incidence of infection, as manifested by febrile neutropenia (FN), in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer medicines associated with a clinically significant incidence of febrile neutropenia (FN). 

Recommended Dosage: The recommended dosage of Ryzneuta is a single subcutaneous (SC) injection of 20 mg administered once per chemotherapy cycle at least 24 hours after cytotoxic chemotherapy. Do not administer this therapeutic drug within 14 days before and <24 hours after administration of cytotoxic chemotherapy.

• Splenic rupture, including fatal cases, may occur after the administration of recombinant human granulocyte colonystimulating factor (rhG-CSF) products, such as Ryzneuta 20 mg/mL. Assess for an enlarged spleen or splenic rupture in those who report left upper abdominal or shoulder pain after receiving this medicine.
  
• Acute respiratory distress syndrome (ARDS) can develop in those receiving rhG-CSF products, such as Efbemalenograstim alfa. Assess patients who develop fever and lung infiltrates or respiratory distress after receiving this therapy for ARDS. Discontinue treatment in those with ARDS.
  
• Critical allergic reactions, including anaphylaxis, can occur in individuals receiving Ryzneuta. Permanently stop treatment in patients with serious allergic reactions. This medicinal product is contraindicated in those with a history of serious allergic reactions to Ryzneuta or other rhG-CSF products such as eflapegrastim, pegfilgrastim, or filgrastim products.
  
• Serious and sometimes fatal sickle cell crises can occur in individuals with sickle cell disorders receiving rhG-CSF products, including Ryzneuta. Discontinue treatment with Ryzneuta if a sickle cell crisis occurs.
  
• Glomerulonephritis may occur in those receiving Ryzneuta. The events of glomerulonephritis resolved after dose reduction or discontinuation of treatment. In case glomerulonephritis is suspected, assess for cause. If causality is likely, consider dose reduction or interruption of treatment.
  
• White blood cell (WBC) counts of 100 × 109 /L or greater may occur in those receiving rhG-CSF products. Monitor complete blood count (CBC) during treatment with Ryzneuta. Discontinue treatment in case a WBC count of 100 × 109 /L or greater occurs.

What documents are required to import RYZNEUTA to India?

RYZNEUTA (efbemalenograstim alfa-vuxw) injections can be imported by patients or government hospitals on the name of the patients only. 

The following documentation is required to import the product:

• A valid prescription from a qualified doctor.
  
• Patients diagnostic reports
  
• Patients ID proof (issued by the government of India)

The order will be confirmed only after the receipt of:

• A valid prescription from Doctor
  
• Import permit if applicable

RYZNEUTA (efbemalenograstim alfa injection) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed.

IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input

• On availability of Ryzneuta in India (Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  
• Medicine Price.
  
• Finding Genuine and reliable sources from the USA, Canada, Europe, and Australia
  
• Ensuring 100% transparency.

IPN (Indian Pharma Network) can facilitate the supply of RYZNEUTA (prescription medicines) to all locations in the world and in India after fulfilling the legal requirement (if applicable).

Please contact +91-9310090915 | Toll-Free Number: 1800-889-1064 or write us at info@indianpharmanetwork.in for Ryzneuta 20 mg/mL price in India. 

We take to guarantee quality and delivery anywhere in the world as per the buyer’s requirements.

Indian Pharma Network is able to source the RYZNEUTA (Cancer Treatment Medicines) from across the globe and has the ability to supply. Indian Pharma offers its customers worldwide access to the best available treatment.

Indian Pharma Network (IPN) is able to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

What is the Generic Name for the trade name drug Ryzneuta®?

Efbemalenograstim alfa-vuxw is a Generic Name for the trade name drug Ryzneuta®.

What is the Manufacturer’s Name of Ryzneuta®?

Ryzneuta® is manufactured by Evive Biotechnology.

Is Ryzneuta® approved by the FDA?

Yes, Ryzneuta® is approved by the FDA. Date of first approval: November 16, 2023.

Where can I get Ryzneuta® at the best price in India?

To get the best Ryzneuta price in India, kindly contact the Indian Pharma Network (a WHO GDP and ISO 9001:2008 certified company). For Ryzneuta®, a medical prescription is needed from a treating physician.

What is the dosage and form of Ryzneuta® supplied?

Ryzneuta® is supplied as an injection: 20 mg/mL solution in a single-dose prefilled syringe for SC administration. 

What are the most common side effects of Ryzneuta®? 

The most common side effects of Ryzneuta® are anemia, nausea, and thrombocytopenia.

How much does Ryzneuta® cost in India?

The cost of Ryzneuta in India can vary. To procure this leukocyte growth factor legally, you can call or WhatsApp +91-9310090915 or send mail to info@indianpharmanetwork.in.

What are the storage conditions of Ryzneuta®?

Store refrigerated at 2-8°C (36-46°F) in the carton to protect from light. Do not shake. Discard syringes stored at room temperature beyond 48 hours. Never freeze it. Discard the syringe in case it is frozen.

Is it safe to buy Ryzneuta® online in India?

Yes, one can buy Ryzneuta online in India at the lowest price from the Indian Pharma Network (IPN) if this medicinal product is not (yet) registered or available in their country. We can help facilitate the supply of Ryzneuta® through legal channels.